drugset / Trial / NCT00003822

SR-45023A in Treating Patients With Advanced Solid Tumors

NCT00003822 ↗

Phase 1 Completed 30 enrolled Genzyme, a Sanofi Company
Treatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of SR-45023A in treating patients who have advanced solid tumors.

Timeline

Start
1998-08
Primary completion
—
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject apomine Small molecule — Oral